Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

被引：0
|
作者：
Jason D. Lickliter
Mark Voskoboynik
Linda Mileshkin
Hui K. Gan
Ganessan Kichenadasse
Kathy Zhang
Maggie Zhang
Zhiyu Tang
Michael Millward
机构：
[1] Nucleus Network,Department of Medicine
[2] Central Clinical School,undefined
[3] Monash University,undefined
[4] Peter MacCallum Cancer Centre-East Melbourne,undefined
[5] Olivia Newton-John Cancer Wellness and Research Centre,undefined
[6] Austin Hospital,undefined
[7] Heidelberg,undefined
[8] La Trobe University School of Cancer Medicine,undefined
[9] University of Melbourne,undefined
[10] Flinders Centre for Innovation in Cancer,undefined
[11] Flinders Medical Centre,undefined
[12] BeiGene USA,undefined
[13] Inc.,undefined
[14] Linear Clinical Research & University of Western Australia,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 585
页数：9
相关论文
共 50 条
  • [21] Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.
    Lee, Dae Ho
    Roohullah, Aflah
    Cho, Byoung Chul
    Lemech, Charlotte Rose
    de Souza, Paul L.
    Millward, Michael
    Choi, Jun Young
    Park, Kyung Eui
    Lee, Minseon
    Kim, YeongMun
    Shin, Youngkee
    Han, Ji-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Safety, anti-tumour activity, and pharmacokinetics of fixed- dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
    Mo, Hongnan
    Huang, Jing
    Xu, Jiachen
    Chen, Xuelian
    Wu, Dawei
    Qu, Dong
    Wang, Xi
    Lan, Bo
    Wang, Xingyuan
    Xu, Jianping
    Zhang, Honggang
    Chi, Yihebali
    Yang, Qing
    Xu, Binghe
    BRITISH JOURNAL OF CANCER, 2018, 119 (05) : 538 - 545
  • [23] Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
    S J Isakoff
    D Wang
    M Campone
    A Calles
    E Leip
    K Turnbull
    N Bardy-Bouxin
    L Duvillié
    E Calvo
    British Journal of Cancer, 2014, 111 : 2058 - 2066
  • [24] Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
    Guo, Ye
    Zhang, Weijie
    Ying, Jieer
    Zhang, Yanqiao
    Pan, Yueyin
    Qiu, Wensheng
    Fan, Qingxia
    Xu, Qi
    Ma, Yue
    Wang, Gang
    Guo, Jing
    Su, Weiguo
    Fan, Songhua
    Tan, Panfeng
    Wang, Yan
    Luo, Yang
    Zhou, Hui
    Li, Jin
    EUROPEAN JOURNAL OF CANCER, 2023, 181 : 26 - 37
  • [25] Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
    Isakoff, S. J.
    Wang, D.
    Campone, M.
    Calles, A.
    Leip, E.
    Turnbull, K.
    Bardy-Bouxin, N.
    Duvillie, L.
    Calvo, E.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2058 - 2066
  • [26] Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors
    Lickliter, J.
    Mileshkin, L.
    Voskoboynik, M.
    Millward, M.
    Freimund, A.
    Meniawy, T.
    Tang, T.
    Wei, R.
    Li, M.
    Paton, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors
    Apostolia Maria Tsimberidou
    Claire F. Verschraegen
    Robert Wesolowski
    Chi-Sheng Shia
    Pei Hsu
    Tillman E. Pearce
    British Journal of Cancer, 2023, 129 : 266 - 274
  • [28] Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors
    Tsimberidou, Apostolia Maria
    Verschraegen, Claire F.
    Wesolowski, Robert
    Shia, Chi-Sheng
    Hsu, Pei
    Pearce, Tillman E.
    BRITISH JOURNAL OF CANCER, 2023, 129 (02) : 266 - 274
  • [29] A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours
    Tan, David Shao Peng
    Ng, Matthew C. H.
    Subbiah, Vivek
    Messersmith, Wells A.
    Strickler, John H.
    Diermayr, Veronica
    Cometa, Julienne
    Blanchard, Stephanie
    Nellore, Ranjani
    Pendharkar, Vishal
    Gan, Bong Hwa
    Rozaini, Nurul Nazihah
    Koh, Claudia
    Sarma, Suman
    Poh, Huay Mei
    Lezhava, Alexander
    Prativadibhayankaram, Venkateshan Srirangam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
12345